EP0131595A1 - Carbostyriloximinopropanolamine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung - Google Patents

Carbostyriloximinopropanolamine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung

Info

Publication number
EP0131595A1
EP0131595A1 EP84900392A EP84900392A EP0131595A1 EP 0131595 A1 EP0131595 A1 EP 0131595A1 EP 84900392 A EP84900392 A EP 84900392A EP 84900392 A EP84900392 A EP 84900392A EP 0131595 A1 EP0131595 A1 EP 0131595A1
Authority
EP
European Patent Office
Prior art keywords
carbostyril
methyl ketone
ketone oxime
propyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP84900392A
Other languages
English (en)
French (fr)
Inventor
Nourdine Amlaiky
Gérard Leclerc
Guy Andermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires POS
Original Assignee
Laboratoires POS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires POS filed Critical Laboratoires POS
Publication of EP0131595A1 publication Critical patent/EP0131595A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof

Definitions

  • the present invention relates to new beta-blocking compounds with a carbostyril nucleus, to their methods of preparation and to their applications in the therapeutic field, in particular as medicaments useful in the cardiovascular and ophthalmic fields.
  • the beta-blocking substances currently marketed belong to:
  • Ateolol of formula:
  • This product is used in the form of eye drops in the treatment of glaucoma and marketed in the form of tablets in the treatment of high blood pressure.
  • the subject of the invention is, as a new product, carbostyriloximinopropanolamines of general formula (A)
  • R 1 is a hydrogen atom, or an alkyl radical containing from 1 to 3 carbon atoms,
  • R 2 is a hydrogen atom, or an alkyloxy, aryloxy radical, containing from 1 to 10 carbon atoms, aliphatic or aromatic,
  • R 3 is an optionally substituted alkyl or arylalkyl radical containing from 2 to 30 carbon atoms, linear or branched, aliphatic or aromatic.
  • arylalkyl radical denotes above radicals preferably comprising from 1 to 6 carbon atoms in the aliphatic part, the aryl part preferably being the phenyl radical, for example benzyl radical, optionally substituted.
  • Compounds A can be saturated at 3,4 or have a double bond at this level.
  • a subject of the invention is also the therapeutically acceptable acid salts of these compounds.
  • These are salts of mineral acids such as phosphoric acid or organic acids, in particular monocarboxylic or dicarboxylic, maleic and fumaric, for example.
  • the salts may be the salts corresponding to the neutralization of one or more of the acid functions.
  • the compounds of the invention have beta-blocking properties. They find a particularly interesting application in the treatment of cardiovascular disorders and in the field of ophthalmology.
  • the compounds of the invention are obtained from the corresponding substituted acetyl-5, R 1 , R 2 (B) of formula
  • R 1 and R 2 are both a hydrogen atom.
  • Extract with chloroform dry over MgSO 4 .
  • Evaporate Chromatograph the product on silica using chloroform as the eluent.
  • Example 1 O- (tertbutylamino- & ol-2 propyl) (8-benzyloxy-carbostyril) -5 methyl ketone oxime.
  • Into a 250 ml flask add 3.6 g (0.01 mole of [(8-benzyloxy-corbostyril) -5 methyl ketone oxime] -3 epoxypropane -1.2 (X),
  • the base is converted into phosphate by dissolving it in water, adding phosphoric acid. Add acetonitrile, allow to crystallize.
  • Example 3 O- (isopropylamino-1 ol-2 propyl) (benzyloxy-8 carbostyril) -5 methyl ketone oxime. Made from [(8-benzyloxy-carbostyril) -5 methyl ketone oxime] -3 epoxypropane -1,2 (X) and isopropylamine, in accordance with Example 1. Yield 60%.
  • Example 5 O- [( ⁇ -methyl ⁇ -phenylethylamino-1) ol-2 propyl] (benzyloxy-8 carbos tyril) -5 methyl ketone oxime.
  • Example 6 Oxalate of O- [( ⁇ -methyl p-phenylethylamino-1) ol-2 propyl] (8-hydroxycarbostyril) -5 methyl ketone oxime (compound No. 5).
  • Example 8 O- [(3,4-dimethoxyphenylethylamino -1) ol-2 propyl] oxalate (8-hydroxy carbostyril) -5 methyl ketone oxime (compound No. 6).
  • Example 9 O- [(3,4-dimethoxyphenylethylamino) -1 ol-2 propyl] (8-benzyloxy-3,4-dihydro-carbostyril) -5 methyl ketone oxime.
  • Example 11 O - [( ⁇ -methyl ⁇ -phenylethylamino) -1 ol-2 propyl] (benzyloxy-8 dihydro -3.4 carbos tyril) -5 methyl cetone oxime.
  • Example 14 O- (1-tertubylamino-2-ol-propyl) oxalate (8-methoxy-3,4-dihydro-carbos tyril) -5 methyl ketone oxime (compound No. 10). Made from (8-methoxy-3,4-dihydro-carbostyril) -5 methyl ketone oxime -3 epoxypropane -1,2 (V) and tertbutylamine, in accordance with Example 1.
  • Example 17 O- (1-isopropylamino-2-ol-propyl) oxalate (8-methoxy-1-methyl-carbostyril) -5 methyl ketone oxime (compound No. 2).
  • the present invention also relates to the use of the compounds of formula A as a medicament, as well than pharmaceutical compositions containing these drugs.
  • compositions according to the present invention can comprise one or more compounds of formula A optionally in combination with other active ingredients.
  • compositions according to the invention are particularly suitable for use as eye drops.
  • the eye drops can contain various other constituents with various functions and playing in particular the roles: of isotonic agents, such as for example sodium chloride or chloride potassium; buffering agents, such as for example sodium or potassium phosphates, sodium borate; optionally preservatives such as non-toxic mercury salts, quaternary ammoniums, chlorhexidine salts.
  • isotonic agents such as for example sodium chloride or chloride potassium
  • buffering agents such as for example sodium or potassium phosphates, sodium borate
  • optionally preservatives such as non-toxic mercury salts, quaternary ammoniums, chlorhexidine salts.
  • the compositions are diluted with distilled water.
  • the usual dose which varies according to the subject to be treated and the condition in question, will be of the order of 1 to 4 applications per day of an eye drop containing 0.1% to 1% of active principle in humans. .
  • the efficacy of the compounds according to the invention is demonstrated by comparative tests which are described in more detail below.
  • the reference compound chosen is Timolol, that is to say the compound of basic formula:
  • the doses of the two compounds are equivalent to 0.5 g% of base.
  • the trials are carried out on series of New Zealand albino rabbits weighing 3.5 to 4.5 kg, operating in double-blind mode, with therapeutic rests between treatments. Measures without treatment were also made, by local anesthesia of the eye of rabbits with posicain, in order to be able to follow the evolution of the intraocular pressure (IOP) in animals.
  • Glaucoma was caused in the right eyes of rabbits by intraocular injection of: alpha-chymo tryps ine according to the SEARS method (Am. J. Ophtalmo 1974, 71p. 378) modified by VAREILLES & Al (Am. J / ophtalmo 1979, 210, P.561).
  • the presence of glaucoma is characterized by the determination of the flow coefficient, from tonographic measurements, the eye being considered to be glaucomatous when this coefficient is less than 0.12 (ZANEN, J .FR. Ophtalmol 1980, 3,9 , pp. 209-218).
  • the IOPs were measured every half hour during the first three hours and then every hour until the 7th hour.
  • the effect of local thesis donkeys was measured, each measurement being made on both eyes at the same time, the results of the left untreated eye being used as control tests.
  • STATISTICAL ANALYSIS determination of the mean and standard deviation of the local anesthetic effect (expressed in number of pulses on the cornea) obtained after instillation of the two compounds A and B in the healthy eye of 8 rabbits.
  • compositions according to the invention on the cornea is generally zero or very weak for the compounds of the invention unlike the case of timolol.
  • hypotensive action does not vary significantly with the concentration for all the products tested.
  • the new eye drops according to the invention have therefore been found to be, in general, excellent therapeutic agents for the treatment of glaucoma.
  • compositions of two eye drops according to the invention are given below, having given excellent results when they have been administered to patients with glaucoma, at the rate of two drops per 24 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP84900392A 1983-01-17 1984-01-10 Carbostyriloximinopropanolamine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung Withdrawn EP0131595A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8300745 1983-01-17
FR8300745A FR2539413A1 (fr) 1983-01-17 1983-01-17 Carbostyriloximinopropanolamines utiles comme medicaments et procede pour leur preparation

Publications (1)

Publication Number Publication Date
EP0131595A1 true EP0131595A1 (de) 1985-01-23

Family

ID=9285057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84900392A Withdrawn EP0131595A1 (de) 1983-01-17 1984-01-10 Carbostyriloximinopropanolamine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung

Country Status (5)

Country Link
EP (1) EP0131595A1 (de)
FR (1) FR2539413A1 (de)
IN (1) IN161149B (de)
IT (1) IT1174468B (de)
WO (1) WO1984002908A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK167187A (da) * 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
KR940000785B1 (ko) * 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
EP0369944A1 (de) * 1988-11-18 1990-05-23 Ciba-Geigy Ag Substituierte Oxadiaminobutane
IL97759A0 (en) * 1990-04-11 1992-06-21 Ciba Geigy Ag Hydroxylamine compounds
WO2004050657A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH619453A5 (de) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
JPS5513241A (en) * 1978-07-14 1980-01-30 Otsuka Pharmaceut Co Ltd Remedy for glaucoma
AU518814B2 (en) * 1979-01-30 1981-10-22 Otsuka Pharamaceutical Co. Glaucoma treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8402908A1 *

Also Published As

Publication number Publication date
IT8419167A0 (it) 1984-01-16
FR2539413B1 (de) 1985-05-03
IN161149B (de) 1987-10-10
FR2539413A1 (fr) 1984-07-20
WO1984002908A1 (fr) 1984-08-02
IT1174468B (it) 1987-07-01

Similar Documents

Publication Publication Date Title
JP4491136B2 (ja) 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
EP0117779B1 (de) Pyridazin-Derivate, wirksam auf das Zentralnervensystem, Verfahren zur Herstellung, und diese enthaltende Arzneimittel
FR2466248A1 (fr) Derives d'agents anti-inflammatoires non steroides, procede de preparation et compositions pharmaceutiques les contenant
FR2552993A1 (fr) Composition pharmaceutique ophtalmique a base d'un derive d'acide phenylacetique
JPH0326183B2 (de)
JPH0211579B2 (de)
JP3801225B2 (ja) アミノアルコール類の塩およびこれを含有する医薬処方物
EP0087378B1 (de) Oximäther von Alkylaminoalkoholen als Heilmittelverbindungen und Verfahren zu ihrer Herstellung
CN116724023A (zh) 作为药物活性化合物的大麻素衍生物及其制备方法
US4743618A (en) Substituted 2-aminotetralins
WO1984002908A1 (fr) Carbostyriloximinopropanolamines utiles comme medicaments et procede pour leur preparation
US5698585A (en) Pharmaceutical preparation for prevention and/or treatment for cataract
JPH0768235B2 (ja) Ｎｍｄａ遮断薬剤組成物
CA1223877A (fr) Carbostyriloximinopropanolamines utiles comme medicaments et procede pour leur preparation
JP2001501627A (ja) 新規ペンタエリスリトール誘導体、その製造方法および使用ならびにその合成のための中間体
JPS6245525A (ja) 脂質低下剤
JPH02275846A (ja) カルボン酸誘導体
EP0737187B1 (de) Benzoxazinderivate, verfahren diese zu erhalten und ihre verwendung als medikamente
JPH037670B2 (de)
EP0215319A2 (de) Gem-Dihalo-1,8-diamino-4-aza-oktane
JP2000509726A (ja) 糖尿病処置用のオキシランカルボン酸
EP0082040B1 (de) 3,7a-Diazacyclohepta(j,k)fluorenderivate, ihre Herstellung und ihre therapeutische Verwendung
JPS58164507A (ja) ジベンゾシクロヘプテニリデン類による免疫変化剤
US4103029A (en) Amino substituted arylthio-alkanoic acids having hypolipidemic activity
FR2714376A1 (fr) N,N-diméthylamino-éthyl-beta-(4-hydroxy-3,5-di-tert.-butyl-phényl)-propionates.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE GB LI NL SE

17P Request for examination filed

Effective date: 19850326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19841018

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ANDERMANN, GUY

Inventor name: AMLAIKY, NOURDINE

Inventor name: LECLERC, GERARD